title: Current treatment options of T cell-associated immunotherapy in multiple myeloma.
abstract: Multiple myeloma (MM) is a complex disease and is presently an incurable malignant plasma cell tumor. Although the introduction of proteasome inhibitor and the immunomodulators markedly improved the effect of myeloma therapy, most patients still suffer from relapse even with an initially effective therapy. Accumulating evidence suggests that immunotherapy is a promising option in treating MM. And T cell plays crucial role through inducing sustained immune response in vivo in the immunotherapy of tumors. In this article, we will discuss progress of several T cell-based immunotherapies with insight into how they eradicate myeloma cells and their disadvantages.
authors.affiliation: Department of Clinical Hematology, Second Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, 710004, China.
authors.forename: Hailing
authors.initials: H
authors.lastname: Liu
authors.affiliation: Department of Pathology, Affiliated Hospital, Wuxi Medical School, Jiangnan University, Wuxi, 214062, Jiangsu, China.
authors.forename: Yunbao
authors.initials: Y
authors.lastname: Pan
authors.affiliation: Department of Clinical Hematology, Second Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, 710004, China.
authors.forename: Shan
authors.initials: S
authors.lastname: Meng
authors.affiliation: Department of Clinical Hematology, Second Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, 710004, China.
authors.forename: Wanggang
authors.initials: W
authors.lastname: Zhang
authors.affiliation: Department of Clinical Hematology, Second Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, 710004, China. zhoufuling@163.com.|Department of Clinical Hematology, Zhongnan Hospital, Wuhan University, No. 169 Donghu Road, Wuchang District, Wuhan, 430071, Hubei, China. zhoufuling@163.com.
authors.forename: Fuling
authors.initials: F
authors.lastname: Zhou
mesh_terms: D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009101:Multiple Myeloma / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*
keywords: CAR-T; Immunotherapy; Multiple myeloma; T cells